(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,4S,6R)-4-(dimethylamino)-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione | 1384954-32-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,4S,6R)-4-(dimethylamino)-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
• CAS: 1384954-32-8
• 化学式: C₃₈H₆₉NO₁₂
• 分子量: 731.965
• InChiKey: WMFZJOPQQREBNL-HNMWVKFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  51
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  163
• 氢给体数：
  3
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  克拉霉素 在 偶氮二异丁腈 、 三正丁基氢锡 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 6.0h， 生成 (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,4S,6R)-4-(dimethylamino)-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
  参考文献：
  名称：

  [EN] MACROLIDE COMPOUND AND ITS USE OF TREATMENT CHRONIC RESPIRATORY DISEASE
  [FR] COMPOSÉ MACROLIDE ET SON UTILISATION POUR LE TRAITEMENT D'UNE MALADIE RESPIRATOIRE CHRONIQUE

  摘要：

  本文提供了大环内酯类化合物及其用于治疗慢性呼吸道疾病的用途。具体而言，提供了式（I）的化合物或其药学上可接受的盐、立体异构体及其应用。这些化合物可用于治疗慢性呼吸道疾病。

  公开号：

  WO2021138847A1

文献信息

• PREPARATION AND UTILITY OF SUBSTITUTED ERYTHROMYCIN ANALOGS
  申请人：GANT Thomas G.

  公开号：US20070281894A1

  公开（公告）日：2007-12-06

  The present disclosure is directed to novel macrolide antibiotics of Formula 1 and pharmaceutically acceptable salts and prodrugs thereof; and the chemical syntheses and medical uses of these novel macrolide antibiotics for the treatment and/or management of infections caused by various aerobic and anaerobic gram-positive and gram-negative microorganisms as well as various mycobacteria.

  本公开涉及一种新型大环内酯抗生素的公式1及其药用可接受的盐和前药；以及这些新型大环内酯抗生素的化学合成和医学用途，用于治疗和/或管理由各种需氧和厌氧革兰氏阳性和阴性微生物以及各种分枝杆菌引起的感染。
• [EN] MACROLIDE COMPOUND AND ITS USE OF TREATMENT CHRONIC RESPIRATORY DISEASE<br/>[FR] COMPOSÉ MACROLIDE ET SON UTILISATION POUR LE TRAITEMENT D'UNE MALADIE RESPIRATOIRE CHRONIQUE
  申请人：BEIJING CONTINENT PHARMACEUTICALS CO LTD

  公开号：WO2021138847A1

  公开（公告）日：2021-07-15

  Provided herein is macrolide compound and its use of treatment chronic respiratory disease. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers and application thereof. The compounds are useful for treating chronic respiratory disease.

  本文提供了大环内酯类化合物及其用于治疗慢性呼吸道疾病的用途。具体而言，提供了式（I）的化合物或其药学上可接受的盐、立体异构体及其应用。这些化合物可用于治疗慢性呼吸道疾病。
• Synthesis and antibacterial activity of desosamine-modified macrolide derivatives
  作者：Nicolas LeTourneau、Pavan Vimal、Dorota Klepacki、Alexander Mankin、Artem Melman

  DOI：10.1016/j.bmcl.2012.05.110

  日期：2012.7

  Structural factors behind erm macrolide resistance were studied through synthesis of new macrolide derivates possessing truncated desosamine sugar moieties and subsequent determination of their antibacterial activity. Synthesized compounds with 2'-deoxy and 3'-desmethyl desosamine rings demonstrated decreased antibacterial activity on the native Staphylococcus aureus strain and were inactive against constitutively resistance S. aureus. The obtained results indicate that steric repulsion between the dimethylated A2058 and desosamine ring cannot be considered as a primary reason for erm-resistance. (C) 2012 Published by Elsevier Ltd.